Yeah- I am a bit surprised at the development but I think the...

Yeah- I am a bit surprised at the development but I think the deal may exceptionally god for MBP.

MBP gets control of Polynovo, and no stock dilution.

Exceed seems to come off the worse.

One nagging concern is that Xceed were never able to raise what seems to me to be a rather piddling amount of cash to fund an enterprise with such potential. Is there a problem lurking in the background?

For example, if Medtronic is serious about the biodegradable stent development, why is it that they could not find a few million to tie up the Polynovo technology lock, stock and barrel. That ought not be too hard for a company with a 60 billion dollar market capitalization.

And, Medtronic has been had the technology under license for nearly three years now, and there isn't s single mention of it - or any other biodegradable stent technology - on the Medtronic website. Seems strange considering the progress reported by Abbott. So, just where is Medtronic in all this?